Fisher Scientific Company L.L.C.

Fisher Scientific Company L.L.C., operating through its Fisher Healthcare division, supplies laboratory reagents, diagnostic consumables, microbiology media, and medical equipment to federal healthcare agencies as a prime contractor on full-and-open competitive procurements, with no set-aside posture. The company is a for-profit limited liability company and subsidiary of Thermo Electron Corporation, headquartered in Pittsburgh, Pennsylvania.

Fisher Healthcare's federal footprint centers on the Department of Veterans Affairs across multiple Veterans Integrated Service Networks (VISNs), the Indian Health Service, the Defense Health Agency, and the Department of Health and Human Services. The vendor competes exclusively in unrestricted competition; no awards in the source carry set-aside designations. Recent representative work includes a $1.084 million purchase order from VISN 22 in February 2026 for oncology reagents and molecular testing consumables (Oncomine Precision Assay kits, Genexus sequencing systems, Qubit assay kits, and SeraseQ quality controls); a $3.196 million purchase order from VISN 16 in July 2025 for reagents and consumables supporting DNA and RNA molecular testing; a $920,681.30 purchase order from VISN 5 in January 2026 for Phadia test kits and allergen/autoimmune testing supplies; and a $668,920.08 purchase order from VISN 22 in March 2025 for Next Generation Sequencing reagents and supplies supporting Ion Torrent platforms.

Customer concentration is acute. The top five funding agencies account for 14 percent of awards by count but anchor the portfolio's dollar value: the Indian Health Service leads with 996 awards valued at $29 million combined potential value, followed by VISN 17 (278 awards, $18 million), the Navy Bureau of Medicine and Surgery (257 awards, $15.4 million), HHS Office of the Assistant Secretary for Administration—primarily CDC BioWatch biological monitoring program support—(219 awards, $12 million), and Army Medical Command (156 awards, $11.9 million). By potential value, VISN 19 ranks second at $26 million across 92 awards. The Indian Health Service, Defense Health Agency, and VA VISNs collectively dominate the customer base.

Fisher Healthcare operates heavily through the GSA Federal Supply Schedule 65-VII (In Vitro Diagnostics, Reagents, Test Kits), which anchors 6,027 task orders valued at $141.7 million in combined potential value. The vendor holds multiple single-award BPAs and indefinite delivery contracts directly with individual VISNs: a $1.0 million microbiology media BPA with VISN 22 (established March 2025, extends through March 2030); a $460.3 million BPA with VISN 4 for microbiology media and supplies (October 2023–September 2028); a $3.84 million Fisher GenExus reagents and maintenance BPA with VISN 19 (May 2023–May 2028); a $4.1 million indefinite delivery contract with VISN 6 for micro reagents and consumables (March 2024–September 2028); a $655.7 million indefinite delivery contract with VISN 16 for Human Papillomavirus testing (May 2025–May 2030); and a $6.0 million BPA with the Defense Health Agency for microbiology media and specimen collection supplies (May 2025–May 2030). These vehicles enable task-order-based procurement across the federal healthcare enterprise.

Activity has declined year over year: 80 awards in 2022, 71 in 2023, 51 in 2024, 40 in 2025, and 15 year-to-date in 2026. Combined potential value across the 13,562 prime awards documented is $1.05 billion. The source does not indicate subcontractor engagement; the vendor's posture is 100 percent prime. Thirty-seven awards carrying $7.4 million in combined potential value reach ultimate completion within the next twenty-four months, surfacing recompete exposure in that window. The vendor's category footprint centers on in-vitro diagnostic substance manufacturing (5,856 awards), medical equipment and supplies wholesale (356 awards), surgical appliance manufacturing (273 awards), and analytical laboratory instrument manufacturing (187 awards), reflecting its core positioning in laboratory diagnostics and medical consumables supply to federal healthcare operations.